undamentalytics Newsletter
Sign in

TG Therapeutics, Inc. (TGTX) stock

Add to watchlist

Add holding +

NASDAQ: TGTX Nasdaq Biotechnology

B Fundamentals grade

TG Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$35

Valuation models combined (3)

Base case. Range ~$25–$41. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

TG Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds243 adding, 154 cuttingOf 53 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter TG Therapeutics files

Where TG Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $800m, up 76.1% on a year earlier, slower than the 81.3% growth a quarter earlier. Free-cash-flow margin rose to 2.2% from -13.0% a year earlier. The diluted share count is down 3.5% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 7 financial-health checks. Our valuation models combined value is $35.85 a share, against a share price of $57.82.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

TG Therapeutics, Inc.'s trailing-twelve-month revenue grew 76.1% year on year, with a free-cash-flow margin of 2.2%. Where it stands out: net margin of 55.2% ranks 5 of 180 biotechnology companies we cover. Where it lags: days sales outstanding of 183 days ranks 96 of 100 biotechnology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 133% year over year while revenue grew 76% — the balance sheet is expanding 57 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 76.1% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Shrinking share count. Diluted shares fell 3.5% in a year, so each share owns more of the business.

Things to watch

  • Growth slowing. The growth rate is 5.2 points lower than a quarter earlier.
  • Volatile shares. Over the past year the shares showed annualised volatility of 46% and a beta of 0.5 against the S&P 500.
  • Gross margin slipping. Gross margin is down 4.6 points on a year ago.
  • Weak cash conversion. Free cash flow was 4% of net income over the last 12 months.
  • Below peers: days sales outstanding. Days sales outstanding of 183 days ranks 96 of 100 biotechnology companies we cover (median 75 days).
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 45.5% ranks 67 of 78 biotechnology companies we cover (median 20.6%).

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.05 against an average estimate of $0.44: missed by 88.6%
Revenue
$240m, up 70.3% on a year earlier
Share reaction
-6.3% in the first session after the results on August 3, 2026, against +3.3% for the S&P 500
Next report
November 2, 2026; average EPS estimate $0.26

TG Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.0%
  • 1 week+9.4%
  • 1 month+10.4%
  • This year+101.1%
  • 1 year+72.4%
  • 5 years+82.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$800M
Operating margin
17.1%
Net margin
55.2%
EPS (TTM, diluted)
$2.77

Growth

Revenue growth
+76.1%
Change in growth rate
−5.2 pts
Share count change
−3.5%

Cash

Free cash flow (TTM)
$17.4M
FCF margin
2.2%
Stock pay % of revenue
10.2%

Earnings

Last results
August 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

TG Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value TG Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.89 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$41 ~$25–$55 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$33 ~$31–$64 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: earnings are positive: price-to-earnings is the better measure
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$25 ~$20–$30 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$35 ~$25–$41 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare TG Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$4.65$8.20$4.10$11.10$52.02$19.00$11.83$17.08$30.10$29.81$59.95
Market value$228m$509m$309m$981m$6.0bn$2.5bn$1.6bn$2.5bn$4.8bn$4.8bn$9.6bn
+ Net debt (− = net cash)−$25m−$57m−$42m−$83m−$523m−$231m−$26m$12m$65m$166m$263m
Enterprise value$203m$452m$268m$897m$5.5bn$2.3bn$1.6bn$2.5bn$4.9bn$5.0bn$9.8bn
Multiples
Price / sales n/mn/mn/mn/mn/mn/mn/m10.9x14.7x7.8x12.0x
Price / earnings ———————n/mn/m10.8x21.6x
Price / free cash flow ——————————n/m
EV / EBITDA ———————122.3x116.5x40.3x72.0x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard TG Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -81.3% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -4078.3%; its worst year was -131521.1%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -6328.4% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 25.7% over five years; stock-based pay has been a median 423.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.95 −66% $960m +56%
Next $2.71 +185% $1.3bn +37%

Next year's EPS estimate has moved −17.5% in 90 days, across 5 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −41.1% on 90 days ago. In the last 30 days, 0 analysts raised TG Therapeutics, Inc.'s forecast and 3 cut it.

Consensus EPS forecast TG Therapeutics, Inc., last 90 days
$0.00 $1.00 $2.00 $3.00 $4.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.61 Current fiscal year, 60 days ago: $1.00 Current fiscal year, 30 days ago: $0.95 Current fiscal year, 7 days ago: $0.95 Current fiscal year, Now: $0.95 $0.95 Next fiscal year, 90 days ago: $3.28 Next fiscal year, 60 days ago: $3.13 Next fiscal year, 30 days ago: $2.96 Next fiscal year, 7 days ago: $2.71 Next fiscal year, Now: $2.71 $2.71

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.61$3.28
60 days ago $1.00$3.13
30 days ago $0.95$2.96
7 days ago $0.95$2.71
Now $0.95$2.71

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.44 $0.05 −88.6%
Mar 2026 $0.28 $0.18 −35.1%
Dec 2025 $0.33 $0.14 −57.5%
Sept 2025 $0.22 $0.16 −26.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold00%
Sell113%

Monthly trend

  1. Oct 20261618
  2. Sep 20261618
  3. Aug 20261618
  4. Jul 20261618

Counts of recommendations published by analysts covering TG Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
27.9%
of tradable shares
Days to cover
16.22
at average volume
Short interest, 1 month
−2%
to October 15, 2026
Held by institutions
75%
of shares
Held by insiders
7.5%
of shares
Employees
399
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +72.4%

$34.78 on October 31, 2025 to $59.95

ThenNowEffect
Revenue (last 12 months) $454m $800m +76.1%
Net margin 13.3% 55.2% +314.7%
P/E multiple 95.1x 21.6x −77.2%
Share count 165m 159m +3.7%

Biggest factor: p/e multiple.

Last 3 years +442.0%

$11.06 on November 3, 2023 to $59.95

ThenNowEffect
Revenue (last 12 months) $24m $800m +3224.3%
P/S multiple 63.7x 12.0x −81.2%
Share count 139m 159m −13.1%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TGTX−64%−38%+44%+76%−1%+101%
Industry peers (median)−35%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TGTX33%33%50%58%42%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TGTX−72%−82%−81%−39%−42%−22%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 93% from December 21, 2020 to June 16, 2022. Getting back needed a 1368% gain, reached on June 26, 2026, 1471 days after the low.

Price behaviour

52-week range
$26.94 – $61.18
From 52-week high
−2.0%
vs 50-day average
+8.1%
vs 200-day average
+36.4%
Volatility (1 year)
46%
Beta vs S&P 500
0.46

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±15.5%
After a week
7 up, 5 down
typical move ±20.6%
After a month
9 up, 3 down
typical move ±20.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 −6.3% +3.3% −5.5% +7.8%
May 6, 2026 +19.2% +1.1% +18.1% +11.2%
February 26, 2026 +1.4% −1.0% −2.1% +7.0%
November 3, 2025 −2.8% −1.0% −12.9% −9.1%
August 4, 2025 −18.9% +1.0% −24.6% −9.5%
May 5, 2025 −19.8% −1.4% −19.5% −14.7%
March 3, 2025 +18.4% −2.9% +30.4% +25.5%
November 4, 2024 −3.9% +1.0% +14.3% +25.9%
August 6, 2024 +16.2% +0.2% +23.4% +24.7%
May 1, 2024 +20.2% +0.6% +25.3% +19.3%
February 28, 2024 +23.8% +0.2% +31.1% +9.3%
November 1, 2023 +34.7% +3.0% +39.6% +78.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

TG Therapeutics, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) TG Therapeutics, Inc.
$0 $200M $400M $600M $800M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $189.8M Revenue (TTM), FY23 Q4: $233.7M Revenue (TTM), FY24 Q1: $289.3M Revenue (TTM), FY24 Q2: $346.7M Revenue (TTM), FY24 Q3: $264.8M Revenue (TTM), FY24 Q4: $329M Revenue (TTM), FY25 Q1: $386.4M Revenue (TTM), FY25 Q2: $454.1M Revenue (TTM), FY25 Q3: $531.9M Revenue (TTM), FY25 Q4: $616.3M Revenue (TTM), FY26 Q1: $700.3M Revenue (TTM), FY26 Q2: $799.5M $799.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $189.8M
FY23 Q4 $233.7M
FY24 Q1 $289.3M
FY24 Q2 $346.7M
FY24 Q3 $264.8M
FY24 Q4 $329M
FY25 Q1 $386.4M
FY25 Q2 $454.1M
FY25 Q3 $531.9M
FY25 Q4 $616.3M
FY26 Q1 $700.3M
FY26 Q2 $799.5M
Revenue growth, TTM YoY TG Therapeutics, Inc.
0% 5000% 10000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 3676.6% Revenue growth, TTM YoY, FY23 Q4: 8293.1% Revenue growth, TTM YoY, FY24 Q1: 3275.7% Revenue growth, TTM YoY, FY24 Q2: 1341.6% Revenue growth, TTM YoY, FY24 Q3: 39.5% Revenue growth, TTM YoY, FY24 Q4: 40.8% Revenue growth, TTM YoY, FY25 Q1: 33.5% Revenue growth, TTM YoY, FY25 Q2: 31.0% Revenue growth, TTM YoY, FY25 Q3: 100.9% Revenue growth, TTM YoY, FY25 Q4: 87.3% Revenue growth, TTM YoY, FY26 Q1: 81.3% Revenue growth, TTM YoY, FY26 Q2: 76.1% 76.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 3676.6%
FY23 Q4 8293.1%
FY24 Q1 3275.7%
FY24 Q2 1341.6%
FY24 Q3 39.5%
FY24 Q4 40.8%
FY25 Q1 33.5%
FY25 Q2 31.0%
FY25 Q3 100.9%
FY25 Q4 87.3%
FY26 Q1 81.3%
FY26 Q2 76.1%
Operating margin (TTM) TG Therapeutics, Inc.
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -23.4% Operating margin (TTM), FY23 Q4: 8.8% Operating margin (TTM), FY24 Q1: 16.7% Operating margin (TTM), FY24 Q2: 29.4% Operating margin (TTM), FY24 Q3: -0.2% Operating margin (TTM), FY24 Q4: 12.7% Operating margin (TTM), FY25 Q1: 15.5% Operating margin (TTM), FY25 Q2: 18.9% Operating margin (TTM), FY25 Q3: 19.3% Operating margin (TTM), FY25 Q4: 20.0% Operating margin (TTM), FY26 Q1: 21.3% Operating margin (TTM), FY26 Q2: 17.1% 17.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -23.4%
FY23 Q4 8.8%
FY24 Q1 16.7%
FY24 Q2 29.4%
FY24 Q3 -0.2%
FY24 Q4 12.7%
FY25 Q1 15.5%
FY25 Q2 18.9%
FY25 Q3 19.3%
FY25 Q4 20.0%
FY26 Q1 21.3%
FY26 Q2 17.1%
FCF margin (TTM) TG Therapeutics, Inc.
-8000% -6000% -4000% -2000% 0% 2000% FY22 Q1 FY22 Q4 FY25 Q1 FY26 Q2 FCF margin (TTM), FY22 Q1: -3580.8% FCF margin (TTM), FY22 Q2: -3908.6% FCF margin (TTM), FY22 Q3: -4762.2% FCF margin (TTM), FY22 Q4: -6328.4% FCF margin (TTM), FY24 Q3: -10.6% FCF margin (TTM), FY24 Q4: -12.3% FCF margin (TTM), FY25 Q1: -15.8% FCF margin (TTM), FY25 Q2: -13.0% FCF margin (TTM), FY25 Q3: -13.2% FCF margin (TTM), FY25 Q4: -4.1% FCF margin (TTM), FY26 Q1: -2.0% FCF margin (TTM), FY26 Q2: 2.2% 2.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q1 -3580.8%
FY22 Q2 -3908.6%
FY22 Q3 -4762.2%
FY22 Q4 -6328.4%
FY24 Q3 -10.6%
FY24 Q4 -12.3%
FY25 Q1 -15.8%
FY25 Q2 -13.0%
FY25 Q3 -13.2%
FY25 Q4 -4.1%
FY26 Q1 -2.0%
FY26 Q2 2.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 7 3 234 329 616 800
Gross profit — — — — — 6 3 220 291 516 659
EBITDA −79 −119 −174 −169 −273 −344 −218 21 42 123 136
Operating income −79 −119 −174 −169 −274 −345 −218 21 42 123 136
Net income −78 −118 −173 −173 −279 −348 −224 13 23 447 441
Diluted EPS −$1.60 −$1.91 −$2.30 −$1.96 −$2.42 −$2.63 −$1.65 $0.09 $0.15 $2.77 $2.77
Growth (year on year)
Revenue — 0.0% 0.0% 0.0% 0.0% +>999% −58.4% +>999% +40.8% +87.3% +76.1%
EBITDA — — — — — — — — +101.5% +193.8% +58.9%
Operating income — — — — — — — — +103.2% +194.1% +58.8%
Net income — — — — — — — — +84.5% +>999% +630.2%
Diluted EPS — — — — — — — — +66.7% +>999% +657.0%
Margins
Gross margin — — — — — 88.2% 90.5% 94.0% 88.3% 83.7% 82.4%
EBITDA margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% 8.9% 12.8% 20.0% 17.1%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% 8.8% 12.7% 20.0% 17.1%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% 5.4% 7.1% 72.6% 55.2%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% −13.4% −12.3% −4.1% 2.2%
Cash flow
Cash from operations −62 −94 −129 −133 −215 −296 −176 −31 −41 −25 18
Capital spending 0 0 0 0 0 0 0 0 0 0 0
Free cash flow −62 −94 −129 −133 −215 −296 −176 −31 −41 −25 17
Stock-based pay 8 16 13 11 80 61 45 38 43 65 81
Free cash flow after stock pay −69 −110 −142 −144 −295 −357 −221 −69 −83 −90 −64
Balance sheet
Cash 25 57 42 113 553 299 102 93 180 79 483
Total debt 0 0 0 29 31 68 77 105 244 246 745
Net debt (negative = net cash) −25 −57 −42 −83 −523 −231 −26 12 65 166 263
Diluted shares 49m 62m 75m 88m 115m 132m 135m 149m 160m 161m 159m
Returned to shareholders
Buybacks — — — — — — 0 0 9 91 178
Total returned — — — — — — 0 0 9 91 178

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $1.6bn
Short-term assets $1.1bnLonger-term assets $494m
What it owes, and who funded it · $1.6bn
Short-term liabilities $268mLonger-term liabilities $767mShareholders' equity $604m
  • Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $268m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.1bn short-term assets against $767m of longer-dated liabilities.
  • More cash than debt $483m of cash against $745m of debt.
  • Debt below 40% of shareholders' equity Debt is 123% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 28% to 123% over five years.
  • A year's operating cash flow covers at least 20% of debt $18m of operating cash flow against $745m of debt.
  • Operating profit covers interest at least five times over Operating income of $136m against $37m of interest.

From TG Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$178M
Returned to shareholders
1025%
of free cash flow
Buybacks, last 3 fiscal years
$100M
Diluted share count
−3.5%
year over year
Total shareholder yield
1.9%
dividends 0.0% + buybacks 1.9% of market value
R&D spending
28.2%
of revenue
Sales & admin spending
37.1%
of revenue
Days sales outstanding
183 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated TGTX TLX ASND IONS RARE NRIX Median
Revenue, last 12 months $800m $804m $814m $874m $717m $702m $56m
Revenue growth, last 12 months 76.1% 55.6% 106.9% −7.4% 17.5% 738.8% 12.6%
Revenue growth, 3-year average 221.5% — — 11.5% 21.2% 117.1% 13.7%
Revenue growth, latest quarter 70.3% — — −40.7% 28.1% >999% 10.2%
Gross margin 82.4% 53.1% 86.8% 98.2% 97.2% — 82.9%
Operating margin 17.1% 3.7% −18.9% −68.0% −73.6% 41.3% −189.4%
Operating margin, 3-year average 21.8% — <−999% −47.0% −90.2% −207.1% −363.5%
Net margin 55.2% −0.9% −31.7% −64.7% −81.7% 42.0% −169.8%
Cash from operations / revenue 2.2% −2.2% 7.5% −56.8% −67.6% 54.0% −168.0%
Free-cash-flow margin 2.2% −5.3% 7.5% −64.2% −68.2% 52.7% −162.4%
Free-cash-flow margin, 3-year average <−999% — <−999% −46.3% −79.3% −141.7% −310.0%
Stock pay / revenue 10.2% 2.4% 16.1% 18.7% 15.1% 5.8% 20.0%
Change in share count −3.5% −2.1% 4.7% −2.8% 4.2% 31.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 76.1% 12.6% 47 of 172
Change in growth rate Growth -5.2pp -0.1pp 106 of 172
Gross margin Profitability 82.4% 82.4% 39 of 75
Operating margin Profitability 17.1% -189.4% 24 of 175
Net margin Profitability 55.2% -157.3% 5 of 180
Free-cash-flow margin Cash generation 2.2% -145.4% 40 of 176
Stock pay as % of revenue Cash generation 10.2% 19.2% 61 of 179
Long-term debt as % of assets Balance sheet 45.5% 20.6% 67 of 78
Change in share count Balance sheet -3.5% 7.9% 8 of 156
Days sales outstanding Balance sheet 183 days 75 days 96 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $607M 98.5% ▲ 93.5%
Licenses $9.4M 1.5% ▼ 38.7%
Royalty $5.6M 60.0% ▲ 601.0%
Other Revenue $3.6M 38.4% ▲ 97.0%
License Revenue $152,000 1.6% 0.0%
Milestone $0 0.0% ▼ 100.0%

From TG Therapeutics, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$6.1B
Institutions reporting
421
Shares held vs prior quarter
▲ 5.4%
Positions opened / closed
96 / 35

Top buyers and sellers, Q2 2026: 243 institutions bought and 154 sold ; the biggest buyer was D. E. Shaw & Co., Inc (+2.8M shares) and the biggest seller Citadel Advisors LLC (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $1.2B 22.1M 19.9% ▼ 0.9%
Vanguard Portfolio Management LLC $438M 8.0M 7.2% ▼ 3.8%
State Street Corp $428M 7.8M 7.0% ▼ 10.0%
Vanguard Capital Management LLC $338M 6.1M 5.5% ▼ 6.9%
Geode Capital Management, LLC $200M 3.6M 3.3% ▲ 4.1%
D. E. Shaw & Co., Inc. $187M 3.4M 3.1% ▲ 476.4%
Soleus Capital Management, L.P. $161M 2.9M 2.6% ▼ 27.3%
Price T Rowe Associates Inc $152M 2.8M 2.5% ▲ 337.4%
Clearbridge Investments, LLC $146M 2.7M 2.4% ▼ 17.5%
Congress Asset Management Co $143M 2.6M 2.3% ▲ 19.9%
Two Sigma Investments, LP $136M 2.5M 2.2% ▲ 60.1%
Goldman Sachs Group Inc $127M 2.3M 2.1% ▲ 1.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not TG Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $437,650 2 trades by 2 insiders · 0% under pre-set plans
Net ▼ $437,650 net selling
Insider Date Trade Shares Price Value
Charney Laurence N Director September 10, 2026 Sell 5,000 $54.96 $274,800
Echelard Yann Director November 24, 2025 Sell 5,000 $32.57 $162,850

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in TG Therapeutics, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Chris Jacobs(R-NY 27):Sale (partial), $1,001 - $15,000, traded September 8, 2020, filed November 6, 2020

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 3, 2026
  • May 6, 2026
  • February 26, 2026
  • November 3, 2025
  • August 4, 2025
  • May 5, 2025

Recent SEC filings

Data status

When each part of this page on TG Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

TG Therapeutics, Inc. in brief

What does TG Therapeutics, Inc. do?
TG Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is TG Therapeutics, Inc.'s stock ticker?
TG Therapeutics, Inc. trades under the ticker TGTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is TG Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, TG Therapeutics, Inc. reported revenue of $800M, 76.1% higher than a year earlier, according to its SEC filings.
What is TG Therapeutics, Inc.'s free cash flow?
TG Therapeutics, Inc.'s free-cash-flow margin is 2.2% of revenue over the trailing twelve months, ranking 40 of the 176 biotechnology companies we cover.
Who are TG Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is TG Therapeutics, Inc. buying back stock, and does it pay a dividend?
TG Therapeutics, Inc. spent $178M on share repurchases over the trailing twelve months, and its diluted share count fell 3.5% over the year.
What is TG Therapeutics, Inc.'s market cap?
On November 2, 2026, TG Therapeutics, Inc.'s market capitalisation was about $9.6B, with a price-to-earnings ratio of 21.6 and net debt of $263M. Market figures come from third-party market data and may be delayed.
How much debt does TG Therapeutics, Inc. have?
TG Therapeutics, Inc.'s debt-to-equity ratio is 123.4%, from its latest balance sheet (28.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are TG Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to TG Therapeutics, Inc. are Telix Pharmaceuticals Ltd, Ascendis Pharma A/s, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc. and Nurix Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against TG Therapeutics, Inc.'s.
Are insiders buying or selling TG Therapeutics, Inc. stock?
Over the last 12 months, TG Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.